@dividend_dynamo_824 you don't know yourself why you are in or how. Interesting sector in which you are also marketing with an interesting concept. Biosimmilar is simply a highly lucrative area if you do it right
@dividend_dynamo_824 is just very lucrative and in principle much simpler than the other concepts, which is why you hopefully also get better and safer margins. But there are also other interesting providers, such as Sandoz. Why did you go in?
@topicswithhead An important approval for a biosimilar candidate is expected in mid-January. So it could continue to go up. Besides, you already said that the sector is simply very interesting 👍🏼